[go: up one dir, main page]

UA97096C2 - Isolated antibody that specifically binds to trail receptor-2 (tr-2) - Google Patents

Isolated antibody that specifically binds to trail receptor-2 (tr-2)

Info

Publication number
UA97096C2
UA97096C2 UAA200804023A UAA200804023A UA97096C2 UA 97096 C2 UA97096 C2 UA 97096C2 UA A200804023 A UAA200804023 A UA A200804023A UA A200804023 A UAA200804023 A UA A200804023A UA 97096 C2 UA97096 C2 UA 97096C2
Authority
UA
Ukraine
Prior art keywords
antibody
specifically binds
trail receptor
isolated antibody
relates
Prior art date
Application number
UAA200804023A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Брайан Гліняк
Ксяо-Донг Янг
Шерон Вонг-Медден
Ян Фольтц
Ксяо Фенг
Елісон Фіч
Стівен Фостер
Рендалл Р. Кетчем
Original Assignee
Емджен Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Емджен Інк. filed Critical Емджен Інк.
Priority claimed from PCT/US2006/033763 external-priority patent/WO2007027713A2/en
Publication of UA97096C2 publication Critical patent/UA97096C2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to an isolated antibody that specifically binds to TRAIL Receptor-2 (TR-2), a polynucleotide encoding the antibody, a host cell, a method of obtaining an antibody. The invention further relates to a pharmaceutical composition comprising the antibody and to use of therapeutically effective amount of antibody for the preparation of medicinal agent for the treatment of cancer in patient.
UAA200804023A 2005-08-31 2006-08-28 Isolated antibody that specifically binds to trail receptor-2 (tr-2) UA97096C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71343305P 2005-08-31 2005-08-31
PCT/US2006/033763 WO2007027713A2 (en) 2005-08-31 2006-08-28 Trail receptor 2 polypeptides and antibodies

Publications (1)

Publication Number Publication Date
UA97096C2 true UA97096C2 (en) 2012-01-10

Family

ID=40079598

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200804023A UA97096C2 (en) 2005-08-31 2006-08-28 Isolated antibody that specifically binds to trail receptor-2 (tr-2)

Country Status (3)

Country Link
CN (1) CN101300273B (en)
UA (1) UA97096C2 (en)
ZA (1) ZA200802575B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522492A (en) * 2009-04-03 2012-09-27 インスティテュート オブ ベーシック メディカル サイエンシズ チャイニーズ アカデミー オブ メディカル サイエンシズ Antigenic determinants recognized by anti-human death receptor DR5 monoclonal antibody AD5-10, derivatives thereof and uses thereof
SG10201505470QA (en) * 2010-04-13 2015-08-28 Medimmune Llc Trail r2-specific multimeric scaffolds
CA2877573A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
CN103333247B (en) * 2013-05-30 2014-10-08 北京东方百泰生物科技有限公司 Novel monoclonal antibody of VEGFR2 and preparation and application thereof
CN106632607A (en) * 2016-12-29 2017-05-10 华东理工大学 Targeting survivin nano antibody as well as preparation method and application thereof
CN108855003B (en) * 2018-06-28 2021-01-05 南开大学 A kind of immunoadsorbent for removing inflammatory factors in blood and preparation method thereof
CN114395034B (en) * 2022-03-24 2022-08-05 中国科学院微生物研究所 Human antibody for efficiently neutralizing novel coronavirus and application thereof
CN120530143A (en) * 2023-01-17 2025-08-22 苏州永心生物科技有限公司 DR5 domain variants and their applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
CN101300273A (en) 2008-11-05
ZA200802575B (en) 2009-01-28
CN101300273B (en) 2013-05-22

Similar Documents

Publication Publication Date Title
NO2017019I1 (en) Diarylhydantoin compound, pharmaceutical composition and use thereof
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
TW200716646A (en) (S)-N-methylnaltrexone
MX2009006704A (en) New compounds.
MX2011010390A (en) Polymer-agent conjugates, particles, compositions, and related methods of use.
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
UA104585C2 (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MX2007008379A (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs.
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
MA32288B1 (en) New antibodies useful for cancer treatment
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MX2009003039A (en) Use of an anti-cd151 antibody in the treatment of cancer.
MX2009010269A (en) Methods of treating cancer by administering human il-18 combinations.
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2007062413A3 (en) Use of parp-1 inhibitors
UA97096C2 (en) Isolated antibody that specifically binds to trail receptor-2 (tr-2)
IL164564A0 (en) Combination therapy for the treatment of cancer
MX2009004890A (en) Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases.
PT1803456E (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours